a trend toward significanceP = 0.068
Compared with nonresponders, this clinical benefit was significantly different only for the MDS-UPDRS Part III ( P = 0.005), with no between-group differences for the MDS-UPDRS Part II or Part IV (Table 3 ). TMS Measures of Excitability The responders manifested a significant reduction in aMT ( P = 0.049) only in the hemisphere corresponding to the most affected hemibody afterward, unlike the nonresponders, who only showed a trend toward significance ( P = 0.068), with no between-group differences (Table 3 ).